Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Lowers Cost of Whole-Genome Sequencing Services

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina today said that it has lowered the cost of its human whole-genome sequencing services to $5,000 per genome for projects of 10 samples or more, and $4,000 for projects of 50 samples or more.

The services are offered through the Illumina Genome Network and compete directly with human whole-genome offerings from Complete Genomics and Life Technologies.

Illumina launched IGN in July 2010, and since that time has received orders for more than 1,000 samples, it said in a statement today. The services use Illumina's HiSeq platform.

Illumina's announcement comes around two weeks after Complete Genomics CEO Clifford Reid said at a conference that the firm shipped 600 genomes to customers in the first quarter of 2011 — a 20 percent increase over estimates that it provided in mid-March.

Complete Genomics currently offers its whole-genome sequencing services for between $5,500 and $9,500 per genome, depending on the size of the order. By the end of the year, the cost will be below $5,000, said Reid.

According to GenomeWeb Daily News sister publication In Sequence, Complete Genomics also expects that by next year it will cut that price to below $3,000 — a price that Reid said would help drive it into the clinical market.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.